PFE vs REPL
Pfizer Inc (PFE) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported PFE revenue for 2025-12-31 was $62.58B. Net income was $7.77B. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
REPL does not have a complete income-statement cache yet.
PFE currently screens at market cap $147.73B and trailing P/E 19.8. REPL currently screens at market cap $825.7M.
Not investment advice. Open the PFE and REPL stock pages for the full models.
Not investment advice.